Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04052204 · ClinicalTrials.gov registry record · Phase 1
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04052204 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 3 participants.
The verdict
NCT04052204, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or enzalutamide in metastatic castration resistant prostate cancer (mCRPC).
Interventions
- DRUG enzalutamide
- DRUG talazoparib
- DRUG Bempegaldesleukin
- DRUG avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-12-30 |
| Est. Completion | 2020-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04052204
The ClinicalTrials.gov registry entry for NCT04052204 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which enzalutamide is the first listed.
NCT04052204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04052204 about?
NCT04052204 is a clinical study titled "Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors". Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or enzalutamide in metastatic castration resistant prostate cancer (mCRPC).
What is the current status of trial NCT04052204?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2019-12-30. Estimated completion is 2020-09-29.
What interventions are being tested in trial NCT04052204?
The interventions under investigation include: enzalutamide (DRUG), talazoparib (DRUG), Bempegaldesleukin (DRUG), avelumab (DRUG).
Who is sponsoring clinical trial NCT04052204?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.